Shares of Oculis Holding AG (NASDAQ:OCS – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the nine brokerages that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $37.38.
OCS has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a report on Thursday, October 15th. Guggenheim decreased their price objective on shares of Oculis to $40.00 and set a “buy” rating for the company in a report on Wednesday, November 4th. Wall Street Zen upgraded shares of Oculis from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Oculis in a research report on Wednesday, October 21st. Finally, JPMorgan Chase & Co. cut their target price on Oculis from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Friday, August 14th.
Get Our Latest Stock Analysis on OCS
Oculis Price Performance
OCS opened at $7.61 on Friday. The firm has a market cap of $441.23 million, a PE ratio of -4.45 and a beta of 0.67. The stock has a 50-day moving average price of $8.92 and a 200-day moving average price of $18.07. Oculis has a 1 year low of $6.78 and a 1 year high of $34.47. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.41 and a quick ratio of 10.41.
Oculis (NASDAQ:OCS – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.10. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.26 million. Oculis had a negative net margin of 8,613.92% and a negative return on equity of 39.24%. Sell-side analysts predict that Oculis will post -1.83 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Oculis
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Alps Advisors Inc. boosted its holdings in shares of Oculis by 40.7% during the 3rd quarter. Alps Advisors Inc. now owns 81,619 shares of the company’s stock valued at $762,000 after acquiring an additional 23,600 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Oculis during the third quarter valued at approximately $74,000. Squarepoint Ops LLC raised its holdings in shares of Oculis by 326.4% during the second quarter. Squarepoint Ops LLC now owns 61,605 shares of the company’s stock valued at $854,000 after purchasing an additional 47,158 shares during the last quarter. Braidwell LP purchased a new position in shares of Oculis during the second quarter valued at approximately $11,570,000. Finally, Bank of America Corp DE lifted its position in Oculis by 9.1% during the first quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock valued at $1,855,000 after purchasing an additional 5,813 shares during the period. Institutional investors own 22.30% of the company’s stock.
Oculis Company Profile
Oculis is a clinical-stage biopharmaceutical company developing treatments for eye diseases. Founded in 2017, the company is headquartered in Switzerland and conducts research and development across multiple locations. Its investigational pipeline includes therapies for conditions such as diabetic macular edema, dry eye disease and optic neuritis. The programs use approaches including topical eye-drop delivery and neuroprotection, with candidates at different stages of clinical development. Oculis focuses on developing treatments for patients worldwide.
Recommended Stories
- Five stocks we like better than Oculis
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
